PO.MCB10.01 · 分子与细胞生物学
利用尿液细胞外囊泡中的miRNA对妇科肿瘤进行无创筛查
Non-invasive screening of gynecologic tumors using miRNAs in urinary extracellular vesicles
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:
妇科恶性肿瘤是全球女性中继乳腺癌之后癌症相关发病率和死亡率的第二大原因。尽管已有有效的筛查项目,但由于对盆腔检查的心理抗拒(例如在日本约为40%)和临床资源受限,多个地区的参与率仍然有限。为解决这一问题,我们探索了一种基于尿液细胞外囊泡(uEV)全面microRNA(miRNA)分析的无创筛查策略。
方法:
本研究纳入了患有妇科疾病的孕妇和非孕妇,以及健康对照者。共采集了456份尿液样本,从中分离出uEV并进行全面的miRNA分析。使用一个包含121例疾病病例(84例恶性肿瘤和37例良性肿瘤)和121例年龄匹配的健康非孕妇对照的子集来建立诊断模型。数据集被随机分为训练集(N=90)和留出集(N=31)以进行性能评估。所得模型随后应用于患有妇科疾病的孕妇和健康孕妇,以评估其泛化能力和诊断性能。
结果:
训练集中疾病病例与健康对照之间的差异表达分析鉴定出25个表达显著变化的miRNA。使用这些差异表达miRNA构建的诊断模型达到了0.907的AUC,敏感性和特异性分别为0.867和0.856。应用于留出集时,该模型保持了高性能(AUC=0.937;敏感性=0.889;特异性=0.944)。无论癌症类型或疾病分期如何,非孕妇中的恶性和良性肿瘤均以高分被检出。尽管未纳入模型训练的健康孕妇显示出较低的预测癌症概率,但患有妇科疾病的孕妇相较其非孕妇对应者显示出略微降低的分数。
结论:
我们的结果表明,尿液uEV-miRNA分析结合机器学习能够对妇科疾病进行准确筛查。这种无创方法可补充常规健康检查并提高妇科筛查率,从而有助于更早诊断和改善预后。
查看英文原文 English abstract
Background:
Gynecologic malignancies constitute the second leading cause of cancer-related morbidity and mortality among women worldwide, following breast cancer. Despite the availability of effective screening programs, participation remains limited in several regions because of psychological reluctance toward pelvic examinations (e.g., approximately 40% in Japan) and constrained clinical resources. To address this issue, we explored a non-invasive screening strategy based on comprehensive microRNA (miRNA) profiling of urinary extracellular vesicles (uEVs).
Methods:
This study enrolled both pregnant and non-pregnant women with gynecologic diseases, along with healthy counterparts. In total, 456 urine samples were collected, from which uEVs were isolated and subjected to comprehensive miRNA profiling. A subset comprising 121 disease cases (84 malignant and 37 benign tumors) and 121 age-matched healthy non-pregnant controls was used to establish a diagnostic model. The dataset was randomly divided into training (N = 90) and holdout (N = 31) sets for performance evaluation. The resulting model was subsequently applied to pregnant women with gynecologic diseases and healthy pregnant women to assess its generalizability and diagnostic performance.
Results:
Differential expression analysis in the training set between disease cases and healthy controls identified 25 miRNAs with significant expression changes. A diagnostic model constructed using these differentially expressed miRNAs achieved an AUC of 0.907, with sensitivity and specificity of 0.867 and 0.856, respectively. When applied to the holdout set, the model maintained high performance (AUC = 0.937; sensitivity = 0.889; specificity = 0.944). Both malignant and benign tumors were detected with high scores in non-pregnant women, irrespective of cancer type or disease stage. Although healthy pregnant women, who were not included in model training, showed low predicted cancer probabilities, pregnant women with gynecologic diseases exhibited slightly reduced scores compared with their non-pregnant counterparts.
Conclusions:
Our results suggest that urinary uEV-miRNA profiling combined with machine learning enables accurate screening of gynecologic diseases. This non-invasive approach may complement general health checkups and enhance gynecologic screening rates, thereby contributing to earlier diagnosis and improved outcomes.
利益披露 Disclosure
H. Matsumiya, None.
A. Satomura,
Craif USA Inc. Employment, Stock Option.
H. Asano, None..
H. Yamazaki, None..
R. Yamamoto, None..
K. Akabane, None..
R. Tamaki, None..
H. Kurosu, None..
K. Ihira, None..
D. Endo, None..
T. Mitamura, None..
Y. Konno, None..
T. Umazume, None.
M. Mikami,
Craif Inc. Employment, Stock Option.
Y. Ichikawa,
Craif Inc. g., Board of Directors, non-salaried role), Stock, Stock Option.
H. Watari, None.